Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has expanded its commercial agreement with Ascend Imaging, increasing coverage for its Xenon MRI platform from four to 19 US states.
The company said the expanded arrangement will enhance sales efforts and strengthen access to healthcare institutions adopting functional lung imaging.
"Our collaboration with Ascend Imaging has already proven highly productive, and we see clear value in their ability to connect us with the right decision-makers at leading institutions," said Polarean chief executive Christopher von Jako.
"By expanding this partnership into additional states, we can further strengthen our commercial reach and accelerate adoption of Xenon MRI, advancing our mission to transform pulmonary medicine and ultimately improving outcomes for patients across the country."
Under the new terms, Ascend Imaging will continue to act as a non-exclusive representative supporting customer engagement and the negotiation of sales. The partnership aims to increase adoption of Polarean’s FDA-approved Xenon MRI technology.
"Xenon MRI is gaining momentum as institutions recognise the value of regional functional lung imaging," added Ascend Imaging president Wesley Adams.
"With hospitals increasingly seeking innovative solutions that are supported by reimbursement, we are excited to expand our partnership with Polarean and help bring this important technology to more patients and providers."